Lakefront Biotherapeutics NV current report, Q1 FY2026

SEC Filing Summary: Form 6-K

Business Context and Reporting Period

This Form 6-K is filed by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in metadata) for the month of March 2026. The filing, dated March 23, 2026, serves to incorporate by reference a press release (Exhibit 99.1) issued on the same date. The registrant is a foreign private issuer based in Mechelen, Belgium, filing under Form 20-F.

Financial Metrics

The provided filing text does not contain specific financial data. There are no disclosed values for revenue, profit, cash flow, margins, debt, or liquidity in this document. The filing acts solely as a conduit for the attached press release, the content of which is not included in the input text.

Material Changes

No material changes to financial performance or operations are described in the text of this Form 6-K. The document references a press release but does not summarize its contents regarding operational or financial shifts.

Guidance, Outlook, and Risks

The filing text does not provide management commentary, future guidance, risk factors, or details on contingencies. It notes that quotes from Henry Gosebruch and Jaideep Dudani are included in the attached Exhibit 99.1, but the text of these quotes is not present in the provided input.

Key Facts for Investor Verification

  • Company Identity: Verify that the filing pertains to Galapagos NV, not Lakefront Biotherapeutics NV.
  • Missing Content: The actual substance of the March 23, 2026, press release (Exhibit 99.1) is not included in this text; investors must locate the full exhibit to understand the announcement.
  • Financial Data: No financial metrics are available in this specific filing text.
  • Management Quotes: Specific statements by Henry Gosebruch and Jaideep Dudani are referenced but not provided.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.